UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 151

Sortiert nach

The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival

Nature communications, 2021-07, Vol.12 (1), p.4098-4098, Article 4098

2021

Link zum Volltext

Verfügbarkeit prüfen

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma

Cancer discovery, 2016-03, Vol.6 (3), p.286-299

2016

Link zum Volltext

Verfügbarkeit prüfen

Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma

Nature communications, 2020-02, Vol.11 (1), p.853-853, Article 853

2020

Link zum Volltext

Verfügbarkeit prüfen

Author Correction: The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival

Nature communications, 2021-07, Vol.12 (1), p.4588-4588, Article 4588

2021

Link zum Volltext

Verfügbarkeit prüfen

Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK–mTORC1 signaling

Breast cancer research and treatment, 2013-08, Vol.141 (1), p.67-78

2013

Link zum Volltext

Verfügbarkeit prüfen

Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides

Journal of medicinal chemistry, 2012-03, Vol.55 (5), p.2251-2264

2012

Link zum Volltext

Verfügbarkeit prüfen

Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification

PloS one, 2013-10, Vol.8 (10), p.e78656

2013

Link zum Volltext

Verfügbarkeit prüfen

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

Molecular cancer, 2012-12, Vol.11 (1), p.91-91, Article 91

2012

Link zum Volltext

Verfügbarkeit prüfen

Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines

Molecular cancer, 2011-11, Vol.10 (1), p.143-143

2011

Link zum Volltext

Verfügbarkeit prüfen

Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer

Current pharmaceutical design, 2013-02, Vol.19 (5), p.818

2013

Link zum Volltext

Verfügbarkeit prüfen

EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity

Future oncology (London, England), 2012-08, Vol.8 (8), p.1015-1029

2012

Link zum Volltext

Verfügbarkeit prüfen

Novel non-terminal tumor sampling procedure using fine needle aspiration supports immuno-oncology biomarker discovery in preclinical mouse models

Journal for immunotherapy of cancer, 2021-06, Vol.9 (6), p.e002894

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacogenetics of non-small cell lung cancer (NSCLC): time to "work it out"?

Current pharmaceutical design, 2014-01, Vol.20 (24), p.3863

2014

Link zum Volltext

Verfügbarkeit prüfen

Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer

Neoplasia (New York, N.Y.), 2013, Vol.15 (1), p.61-IN18

2013

Link zum Volltext

Verfügbarkeit prüfen

Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy

Nature cancer, 2020-02, Vol.1 (2), p.210

2020

Link zum Volltext

Verfügbarkeit prüfen

Thymidylate synthase inhibitors for thoracic tumors

Pteridines, 2013-06, Vol.24 (1), p.57-67

2013

Link zum Volltext

Verfügbarkeit prüfen

T cell immune awakening in response to immunotherapy is age-dependent

European journal of cancer (1990), 2022-02, Vol.162, p.11-21

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models

Cancer biology & therapy, 2024-12, Vol.25 (1), p.2296048-2296048

2024

Link zum Volltext

Verfügbarkeit prüfen

Tumour infiltrating B cells discriminate checkpoint blockade-induced responses

European journal of cancer (1990), 2022-12, Vol.177, p.164-174

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1584: Efficacy and pharmacodynamic effect of anti-CD73/PD-L1 monoclonal antibodies in combination with chemotherapy: Observations from mouse tumor models

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1584-1584

2021

Link zum Volltext

Verfügbarkeit prüfen

Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells

Molecular cancer therapeutics, 2012-08, Vol.11 (8), p.1735-1746

2012

Link zum Volltext

Verfügbarkeit prüfen

Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met―driven Pancreatic Carcinoma

Cancer research (Chicago, Ill.), 2013-11, Vol.73 (22), p.6745-6756

2013

Link zum Volltext

Verfügbarkeit prüfen

Thymidylate synthase inhibitors for non-small cell lung cancer

Expert opinion on investigational drugs, 2011-10, Vol.20 (10), p.1343-1356

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3207: Influence of tumor mutation burden on response to anti-PD-1 treatment in murine models of melanoma

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3207-3207

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5024: Implications of MAPK pathway inhibition on monocytes and tumor-associated macrophages in melanoma

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.5024-5024

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 151

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(132)
Mit Volltextzugriff
(133)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(55)
Life Sciences & Biomedicine
(49)
Humans
(47)
Oncology
(24)
Antineoplastic Agents - Pharmacology
(18)
Cell Line, Tumor
(17)
Animals
(15)
Female
(15)
Pharmacology & Pharmacy
(14)
Mice
(13)
Chemistry, Medicinal
(11)
Tumors
(11)
Protein Kinase Inhibitors - Pharmacology
(10)
Kinases
(9)
Aged
(8)
Immunotherapy
(8)
Male
(8)
Middle Aged
(8)
Xenograft Model Antitumor Assays
(8)
Antineoplastic Agents - Chemistry
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma

Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma

Author Correction: The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival

Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK–mTORC1 signaling

Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides

Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines

Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer

EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity

Novel non-terminal tumor sampling procedure using fine needle aspiration supports immuno-oncology biomarker discovery in preclinical mouse models

Pharmacogenetics of non-small cell lung cancer (NSCLC): time to "work it out"?

Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer

Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy

Thymidylate synthase inhibitors for thoracic tumors

T cell immune awakening in response to immunotherapy is age-dependent

Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models

Tumour infiltrating B cells discriminate checkpoint blockade-induced responses

Abstract 1584: Efficacy and pharmacodynamic effect of anti-CD73/PD-L1 monoclonal antibodies in combination with chemotherapy: Observations from mouse tumor models

Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells

Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met―driven Pancreatic Carcinoma

Thymidylate synthase inhibitors for non-small cell lung cancer

Abstract 3207: Influence of tumor mutation burden on response to anti-PD-1 treatment in murine models of melanoma

Abstract 5024: Implications of MAPK pathway inhibition on monocytes and tumor-associated macrophages in melanoma

Suchergebnisse filtern